Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
Author:
Ji Jiali, Wang KeORCID, Meng Xinmin, Zhong Hongqin, Li Xiyue, Zhao Hongqing, Xie Guijuan, Xie Yunying, Wang Xun, Zhu Xue
Abstract
Lung adenocarcinoma (LADC), the most common type of lung cancer, is still one of the most aggressive and rapidly fatal tumor types, even though achievements in new therapeutic approaches have been developed. Elaiophylin as a C2 symmetrically glycosylated 16 macrolides has been reported to be a late-stage autophagy inhibitor with a potent anti-tumor effect on various cancers. This study investigated the anti-tumor effect of elaiophylin on human LADC for the first time in in vitro and in vivo models. The in vitro study in LADC A549 cells showed that elaiophylin significantly inhibited cell viability and induced cell apoptosis through the suppression of mitophagy and induction of cellular and mitochondrial oxidative stress. Proteomic analysis and molecular docking assay implicated that SIRT1 was likely the direct target of elaiophylin in A549 cells. Further mechanistic study verified that elaiophylin reduced Nrf2 deacetylation, expression, and transcriptional activity as well as cytoplasm translocation by downregulating SIRT1 expression and deacetylase activity. Additionally, SIRT1/Nrf2 activation could attenuate elaiophylin-induced mitophagy inhibition and oxidative stress. The in vivo study in the A549-xenograft mice model showed that the anti-tumor effect of elaiophylin was accompanied by the decreased expressions of SIRT1, Nrf2, Parkin, and PINK1. Thus, the present study reports that elaiophylin has potent anti-tumor properties in LADC, which effect is likely mediated through suppressing the SIRT1/Nrf2 signaling. In conclusion, elaiophylin may be a novel drug candidate for LADC and SIRT1 may be a new therapeutic target for such devastating malignancy.
Funder
Major Project of the Wuxi Commission of Health Research Project Fund from Wuxi Municipal Health Commission Natural Science Fund Project of Guangxi Province of China Innovation Project of Guangxi Graduate Education
Subject
Cancer Research,Oncology
Reference64 articles.
1. Non-small cell lung cancer: Current treatment and future advances;Zappa;Transl. Lung Cancer Res.,2016 2. Han, Y., Tian, E., Xu, D., Ma, M., Deng, Z., and Hong, K. (2016). Halichoblelide D, a new elaiophylin derivative with potent cytotoxic activity from mangrove-derived Streptomyces sp. 219807. Molecules, 21. 3. Enhancement of the antifungal activity of rapamycin by the coproduced elaiophylin and nigericin;Fang;J. Antibiot.,2000 4. Gui, M., Zhang, M.-X., Wu, W.-H., and Sun, P. (2019). Natural occurrence, bioactivity and biosynthesis of elaiophylin analogues. Molecules, 24. 5. Lim, H.N., Jang, J.-P., Han, J.M., Jang, J.-H., Ahn, J.S., and Jung, H.J. (2018). Antiangiogenic potential of microbial metabolite elaiophylin for targeting tumor angiogenesis. Molecules, 23.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|